June 2022
-
Media ReleaseNovartis acquires Kedalion Therapeutics and its innovative ocular delivery platform that could transform patient experienceNovartis acquires AcuStream™ platform, a novel topical ocular delivery device designed to facilitate dosing precision with the potential to support the delivery of front-of-eye therapies and help…
-
Media ReleaseNovartis expands Beacon of Hope through alliances with Historically Black Medical Schools to address systemic health disparitiesNovartis commits additional $17.7 million to create Clinical Trial Centers of Excellence at Howard University College of Medicine, Meharry Medical College and Charles R. Drew University of Medicine…
-
Media ReleaseNovartis Scemblix®, with novel mechanism of action, shows superior, long-term efficacy and consistent tolerability in 96-week follow-up of chronic myeloid leukemia trialScemblix® (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif®* (bosutinib) at 96 weeks (37.6% vs. 15.8%), building on 24-…
April 2022
-
Media ReleaseNovartis presents new four-year data on efficacy and safety of Kesimpta® (ofatumumab) in people living with relapsing multiple sclerosisPhase 3 ASCLEPIOS I/II trials and the ALITHIOS open-label extension demonstrated the efficacy and safety of continuous Kesimpta® (ofatumumab) treatment and in those switched from teriflunomide, with…
-
Media ReleaseFDA approves Novartis Vijoice® (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS)Vijoice is first approved treatment to specifically address the root cause of PROS conditions in select patients 2 years of age and older1 PROS is a spectrum of rare conditions and is characterized…
December 2021
-
Media ReleaseNovartis Cosentyx® receives FDA approval for the treatment of children and adolescents with enthesitis-related arthritis and psoriatic arthritisNew approvals are based on JUNIPERA trial data showing Cosentyx® (secukinumab) demonstrated reduced flare risk versus placebo and improvement in disease activity observed over two years across both…
-
Media ReleaseFDA approves Novartis Leqvio® (inclisiran), first-in-class siRNA to lower cholesterol and keep it low with two doses a yearWith two maintenance doses a year, Leqvio is the first and only FDA-approved small interfering RNA (siRNA) therapy for LDL-C (bad cholesterol) reduction(1) Leqvio provides effective and sustained…
-
Media ReleaseNovartis announces T-Charge™, next-generation CAR-T platform with first-in-human data at ASH 2021T-Charge, a next-generation platform that aims to revolutionize CAR-T cell therapy, will serve as foundation for various investigational CAR-T therapies Early data from first-in-human dose-…